Medicamen Biotech Limited (MEDICAMEQ.BO)
INR 562.7
(1.74%)
INR 562.7
(1.74%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 245.66 Million INR | -15.55% |
| 2022 | 277.11 Million INR | 4.23% |
| 2021 | 258.06 Million INR | 26.52% |
| 2020 | 204.25 Million INR | -6.05% |
| 2019 | 214.11 Million INR | 3.0% |
| 2018 | 211.19 Million INR | 12.47% |
| 2017 | 186.69 Million INR | 62.19% |
| 2016 | 118.91 Million INR | 98.12% |
| 2015 | 62.29 Million INR | 15.93% |
| 2014 | 61.41 Million INR | 10.13% |
| 2013 | 58.34 Million INR | 696.87% |
| 2012 | -6.93 Million INR | -128.9% |
| 2011 | 27.73 Million INR | -65.2% |
| 2010 | 74.5 Million INR | -10.18% |
| 2009 | 82.94 Million INR | 98.71% |
| 2008 | 40.83 Million INR | -2.96% |
| 2007 | 43.01 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 34.46 Million INR | -36.17% |
| 2023 FY | - INR | -15.55% |
| 2023 Q1 | 73.3 Million INR | 7.24% |
| 2023 Q2 | 51.94 Million INR | -29.14% |
| 2023 Q3 | 57.23 Million INR | 10.18% |
| 2023 Q4 | 57.5 Million INR | 0.47% |
| 2022 FY | - INR | 4.23% |
| 2022 Q4 | 68.35 Million INR | 5.07% |
| 2022 Q3 | 65.05 Million INR | 2.08% |
| 2022 Q2 | 63.73 Million INR | -3.72% |
| 2022 Q1 | 66.19 Million INR | 24.73% |
| 2021 Q2 | 67.03 Million INR | 9.54% |
| 2021 FY | - INR | 26.52% |
| 2021 Q3 | 71.36 Million INR | 6.46% |
| 2021 Q1 | 61.19 Million INR | 25.52% |
| 2021 Q4 | 53.07 Million INR | -25.63% |
| 2020 Q1 | 41.7 Million INR | 2.92% |
| 2020 Q2 | 56.76 Million INR | 36.12% |
| 2020 Q3 | 52.55 Million INR | -7.41% |
| 2020 Q4 | 48.75 Million INR | -7.23% |
| 2020 FY | - INR | -6.05% |
| 2019 FY | - INR | 3.0% |
| 2019 Q2 | 60.56 Million INR | 19.9% |
| 2019 Q3 | 58.88 Million INR | -2.78% |
| 2019 Q1 | 50.51 Million INR | 3.8% |
| 2019 Q4 | 40.51 Million INR | -31.19% |
| 2018 Q4 | 48.66 Million INR | 9.32% |
| 2018 Q2 | 59.45 Million INR | 10.61% |
| 2018 FY | - INR | 12.47% |
| 2018 Q1 | 53.74 Million INR | 12.43% |
| 2018 Q3 | 44.51 Million INR | -25.12% |
| 2017 Q2 | 44.91 Million INR | 8.11% |
| 2017 Q3 | 47.13 Million INR | 4.92% |
| 2017 Q4 | 47.8 Million INR | 1.43% |
| 2017 FY | - INR | 62.19% |
| 2017 Q1 | 41.54 Million INR | 41.78% |
| 2016 Q1 | 25.84 Million INR | -26.04% |
| 2016 FY | - INR | 98.12% |
| 2016 Q4 | 29.3 Million INR | -4.69% |
| 2016 Q2 | 27.23 Million INR | 5.35% |
| 2016 Q3 | 30.74 Million INR | 12.91% |
| 2015 FY | - INR | 15.93% |
| 2015 Q3 | -3.06 Million INR | -119.81% |
| 2015 Q4 | 34.94 Million INR | 1241.63% |
| 2015 Q2 | 15.45 Million INR | 58.24% |
| 2015 Q1 | 9.76 Million INR | -11.74% |
| 2014 Q4 | 11.06 Million INR | 45.79% |
| 2014 Q1 | 13.13 Million INR | 93.68% |
| 2014 Q2 | 18.52 Million INR | 41.08% |
| 2014 FY | - INR | 10.13% |
| 2014 Q3 | 7.58 Million INR | -59.03% |
| 2013 Q3 | 6.04 Million INR | -68.55% |
| 2013 Q2 | 19.22 Million INR | 29.95% |
| 2013 Q4 | 6.77 Million INR | 12.15% |
| 2013 FY | - INR | 696.87% |
| 2013 Q1 | 14.79 Million INR | 816.9% |
| 2012 Q2 | -1.17 Million INR | -148.49% |
| 2012 Q4 | -2.06 Million INR | 66.26% |
| 2012 FY | - INR | -128.9% |
| 2012 Q1 | 2.41 Million INR | -92.96% |
| 2012 Q3 | -6.11 Million INR | -421.4% |
| 2011 Q4 | 34.36 Million INR | 9946.36% |
| 2011 FY | - INR | -65.2% |
| 2011 Q2 | -6.27 Million INR | 0.0% |
| 2011 Q3 | -349 Thousand INR | 94.44% |
| 2010 FY | - INR | -10.18% |
| 2009 FY | - INR | 98.71% |
| 2008 FY | - INR | -2.96% |
| 2008 Q4 | -548 Thousand INR | 0.0% |
| 2007 FY | - INR | 0.0% |
| 2007 Q4 | 14.72 Million INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Ajanta Pharma Limited | 12.56 Billion INR | 98.045% |
| Amrutanjan Health Care Limited | 682.53 Million INR | 64.008% |
| Sigachi Industries Limited | 883.39 Million INR | 72.191% |
| Bal Pharma Limited | 345.59 Million INR | 28.916% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 96.42% |
| Medico Remedies Limited | 150.37 Million INR | -63.362% |
| Lasa Supergenerics Limited | -65.08 Million INR | 477.474% |
| Venus Remedies Limited | 711.8 Million INR | 65.488% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 106.584% |
| Alpa Laboratories Limited | 86.12 Million INR | -185.23% |
| Nectar Lifesciences Limited | 1.56 Billion INR | 84.291% |
| Shilpa Medicare Limited | 2.58 Billion INR | 90.508% |
| Aarti Drugs Limited | 3.24 Billion INR | 92.438% |
| Lupin Limited | 36.96 Billion INR | 99.336% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 99.602% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 99.563% |
| Windlas Biotech Limited | 781.72 Million INR | 68.574% |
| Suven Life Sciences Limited | -992.78 Million INR | 124.745% |
| Eris Lifesciences Limited | 6.98 Billion INR | 96.484% |
| Valiant Laboratories Limited | 12.73 Million INR | -1828.409% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 97.368% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 108.705% |
| Ipca Laboratories Limited | 13.29 Billion INR | 98.153% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 83.39% |
| Achyut Healthcare Limited | 524 Thousand INR | -46781.679% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.822% |
| Bajaj HealthCare Limited | 444.51 Million INR | 44.735% |
| RPG Life Sciences Limited | 1.28 Billion INR | 80.83% |
| Mankind Pharma Limited | 28.09 Billion INR | 99.126% |
| Laurus Labs Limited | 8 Billion INR | 96.932% |
| Piramal Pharma Limited | 13.05 Billion INR | 98.118% |
| Syncom Formulations (India) Limited | 430.27 Million INR | 42.906% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 99.298% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 97.445% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 97.834% |
| Unichem Laboratories Limited | 742.35 Million INR | 66.908% |
| Sequent Scientific Limited | 549.8 Million INR | 55.318% |
| Novartis India Limited | 1.26 Billion INR | 80.646% |
| Wanbury Limited | 985.49 Million INR | 75.072% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 94.748% |
| Wockhardt Limited | 1.08 Billion INR | 77.254% |
| Themis Medicare Limited | 562.6 Million INR | 56.335% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | 24.052% |
| Jubilant Pharmova Limited | 8 Billion INR | 96.932% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 96.42% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 99.722% |
| Divi's Laboratories Limited | 25.43 Billion INR | 99.034% |
| NATCO Pharma Limited | 18.79 Billion INR | 98.693% |
| Gufic Biosciences Limited | 1.48 Billion INR | 83.407% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 90.575% |
| Ind-Swift Limited | 1.06 Billion INR | 76.935% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 91.85% |
| FDC Limited | 4.4 Billion INR | 94.419% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 396.953% |
| Granules India Limited | 8.6 Billion INR | 97.145% |
| Alkem Laboratories Limited | 24.19 Billion INR | 98.985% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 89.577% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -1780.723% |
| Brooks Laboratories Limited | 41.72 Million INR | -488.717% |
| Megasoft Limited | 284.73 Million INR | 13.722% |
| ZIM Laboratories Limited | 462.09 Million INR | 46.838% |
| Strides Pharma Science Limited | 3.76 Billion INR | 93.475% |
| Neuland Laboratories Limited | 4.74 Billion INR | 94.826% |
| Morepen Laboratories Limited | 1.72 Billion INR | 85.767% |
| Hikal Limited | 2.69 Billion INR | 90.875% |
| Indoco Remedies Limited | 2.64 Billion INR | 90.719% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 93.716% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | 14.531% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -40.42% |
| Hester Biosciences Limited | 539.47 Million INR | 54.463% |